Cargando…
Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses
The influenza A virus is notoriously known for its ability to cause recurrent epidemics and global pandemics. Antiviral therapy is effective when treatment is initiated within 48 h of symptom onset, and delaying treatment beyond this time frame is associated with decreased efficacy. Research on anti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125926/ https://www.ncbi.nlm.nih.gov/pubmed/26022197 http://dx.doi.org/10.1016/j.antiviral.2015.05.008 |
_version_ | 1783516048634413056 |
---|---|
author | Liu, Rui An, Liwei Liu, Ge Li, Xiaoyu Tang, Wei Chen, Xulin |
author_facet | Liu, Rui An, Liwei Liu, Ge Li, Xiaoyu Tang, Wei Chen, Xulin |
author_sort | Liu, Rui |
collection | PubMed |
description | The influenza A virus is notoriously known for its ability to cause recurrent epidemics and global pandemics. Antiviral therapy is effective when treatment is initiated within 48 h of symptom onset, and delaying treatment beyond this time frame is associated with decreased efficacy. Research on anti-inflammatory therapy to ameliorate influenza-induced inflammation is currently underway and seems important to the impact on the clinical outcome. Both antiviral and anti-inflammatory drugs with novel mechanisms of action are urgently needed. Current methods for evaluating the efficacy of anti-influenza drugs rely mostly on transformed cells and animals. Transformed cell models are distantly related to physiological and pathological conditions. Although animals are the best choices for preclinical drug testing, they are not time- or cost-efficient. In this study, we established an ex vivo model using mouse lung slices to evaluate both antiviral and anti-inflammatory agents against influenza virus infection. Both influenza virus PR8 (H1N1) and A/Human/Hubei/3/2005 (H3N2) can replicate efficiently in mouse lung slices and trigger significant cytokine and chemokine responses. The induction of selected cytokines and chemokines were found to have a positive correlation between ex vivo and in vivo experiments, suggesting that the ex vivo cultured lung slices may closely resemble the lung functionally in an in vivo configuration when challenged by influenza virus. Furthermore, a set of agents with known antiviral and/or anti-inflammatory activities were tested to validate the ex vivo model. Our results suggested that mouse lung slices provide a robust, convenient and cost-efficient model for the assessment of both antiviral and anti-inflammatory agents against influenza virus infection in one assay. This ex vivo model may predict the efficacy of drug candidates’ antiviral and anti-inflammatory activities in vivo. |
format | Online Article Text |
id | pubmed-7125926 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71259262020-04-08 Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses Liu, Rui An, Liwei Liu, Ge Li, Xiaoyu Tang, Wei Chen, Xulin Antiviral Res Article The influenza A virus is notoriously known for its ability to cause recurrent epidemics and global pandemics. Antiviral therapy is effective when treatment is initiated within 48 h of symptom onset, and delaying treatment beyond this time frame is associated with decreased efficacy. Research on anti-inflammatory therapy to ameliorate influenza-induced inflammation is currently underway and seems important to the impact on the clinical outcome. Both antiviral and anti-inflammatory drugs with novel mechanisms of action are urgently needed. Current methods for evaluating the efficacy of anti-influenza drugs rely mostly on transformed cells and animals. Transformed cell models are distantly related to physiological and pathological conditions. Although animals are the best choices for preclinical drug testing, they are not time- or cost-efficient. In this study, we established an ex vivo model using mouse lung slices to evaluate both antiviral and anti-inflammatory agents against influenza virus infection. Both influenza virus PR8 (H1N1) and A/Human/Hubei/3/2005 (H3N2) can replicate efficiently in mouse lung slices and trigger significant cytokine and chemokine responses. The induction of selected cytokines and chemokines were found to have a positive correlation between ex vivo and in vivo experiments, suggesting that the ex vivo cultured lung slices may closely resemble the lung functionally in an in vivo configuration when challenged by influenza virus. Furthermore, a set of agents with known antiviral and/or anti-inflammatory activities were tested to validate the ex vivo model. Our results suggested that mouse lung slices provide a robust, convenient and cost-efficient model for the assessment of both antiviral and anti-inflammatory agents against influenza virus infection in one assay. This ex vivo model may predict the efficacy of drug candidates’ antiviral and anti-inflammatory activities in vivo. Elsevier B.V. 2015-08 2015-05-26 /pmc/articles/PMC7125926/ /pubmed/26022197 http://dx.doi.org/10.1016/j.antiviral.2015.05.008 Text en Copyright © 2015 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Liu, Rui An, Liwei Liu, Ge Li, Xiaoyu Tang, Wei Chen, Xulin Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
title | Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
title_full | Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
title_fullStr | Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
title_full_unstemmed | Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
title_short | Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
title_sort | mouse lung slices: an ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125926/ https://www.ncbi.nlm.nih.gov/pubmed/26022197 http://dx.doi.org/10.1016/j.antiviral.2015.05.008 |
work_keys_str_mv | AT liurui mouselungslicesanexvivomodelfortheevaluationofantiviralandantiinflammatoryagentsagainstinfluenzaviruses AT anliwei mouselungslicesanexvivomodelfortheevaluationofantiviralandantiinflammatoryagentsagainstinfluenzaviruses AT liuge mouselungslicesanexvivomodelfortheevaluationofantiviralandantiinflammatoryagentsagainstinfluenzaviruses AT lixiaoyu mouselungslicesanexvivomodelfortheevaluationofantiviralandantiinflammatoryagentsagainstinfluenzaviruses AT tangwei mouselungslicesanexvivomodelfortheevaluationofantiviralandantiinflammatoryagentsagainstinfluenzaviruses AT chenxulin mouselungslicesanexvivomodelfortheevaluationofantiviralandantiinflammatoryagentsagainstinfluenzaviruses |